Study of IDO Inhibitor and Temozolomide for Adult Patients With Primary Malignant Brain Tumors
|
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
| ClinicalTrials.gov Identifier: NCT02052648 |
|
Recruitment Status :
Completed
First Posted : February 3, 2014
Last Update Posted : May 28, 2020
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Glioblastoma Multiforme Glioma Gliosarcoma Malignant Brain Tumor | Drug: Indoximod Drug: Temozolomide Drug: Bevacizumab Radiation: Stereotactic Radiation | Phase 1 Phase 2 |
The aim of this study is to identify the safety profile and the recommended dose for phase 2 study of the combination of indoximod (portion 1, phase 1b study). Investigators will then evaluate the tolerability and the preliminary activity in patients with recurrent GBM in three different situations:
- Combination of indoximod and temozolomide (bevacizumab-naive patients)
- Combination of indoximod and temozolomide in patients currently receiving or having received and failed bevacizumab.
- Combination of indoximod and temozolomide with stereotactic radiation. Ancillary studies will be conducted to assess the correlation between intra-tumoral IDO expression or serum biomarkers (immune monitoring) and treatment efficacy.
If the current study shows an acceptable safety profile and suggests preliminary evidence of activity, this will provide the justification for subsequent randomized phase 2 studies in refractory glioblastoma multiforme (GBM).
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 160 participants |
| Allocation: | Non-Randomized |
| Intervention Model: | Parallel Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | A Phase I/II Study of the Combination of Indoximod and Temozolomide for Adult Patients With Temozolomide-Refractory Primary Malignant Brain Tumors |
| Study Start Date : | March 2014 |
| Actual Primary Completion Date : | April 18, 2018 |
| Actual Study Completion Date : | June 20, 2019 |
| Arm | Intervention/treatment |
|---|---|
|
Experimental: Phase 1b Cohort 1
Phase 1B patients will receive Indoximod given in escalating doses. Initial dosing will be 600 mg BID by mouth with escalation planned to 1200 mg BID by mouth. The medication should be taken twice daily for 28 days each cycle. Temozolomide will also be given by mouth at 150 mg/m^2 x 5 days at all dosing levels of indoximod. Each cycle is 28 days. Patients will continue until they experience disease progression or toxicity. |
Drug: Indoximod
Other Names:
Drug: Temozolomide Other Names:
|
|
Experimental: Cohort 2a
Bevacizumab naïve phase II patients who will receive indoximod with temozolomide. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2.
|
Drug: Indoximod
Other Names:
Drug: Temozolomide Other Names:
|
|
Experimental: Cohort 2b
Phase II patients who will receive indoximod with temozolomide and bevacizumab who have previously been treated with bevacizumab. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Bevacizumab will be dosed at 10mg/kg. |
Drug: Indoximod
Other Names:
Drug: Temozolomide Other Names:
Drug: Bevacizumab Other Name: Avastin |
|
Experimental: Cohort 2c
Phase II patients who will receive indoximod with temozolomide and stereotactic radiosurgery. Indoximod will be dosed at 1200mg BID. Temozolomide will be dosed at 150 mg/m2 and may be escalated up to 200 mg/m2. Single fraction SRS dose will be 16 or 20 Gy depending on target volume. The total 5-fraction SRT dose will be 27.5 Gy.
|
Drug: Indoximod
Other Names:
Drug: Temozolomide Other Names:
Radiation: Stereotactic Radiation Other Name: SRS or SRT |
- Phase 1: Determine Phase 2 Dosing [ Time Frame: 3 months ]
Phase 1b component:
Primary objective is to determine the recommended Phase 2 dose of indoximod and temozolomide in combination for treatment of progressive high-grade glioma (including glioblastoma multiforme) or gliosarcoma.
- Phase 2: Efficacy [ Time Frame: 18 months ]Six-month progression-free survival.
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 1 year ]
Phase 1b component:
To determine the adverse event profile (event type, incidence severity, duration causality and treatment intervention) and identify regimen-limiting toxicities (RLT) of indoximod plus temozolomide in combination therapy.
Specifically, investigators define regimen-limiting toxicity (RLT) as a toxicity that delays the planned administration of the next cycle of the backbone chemotherapy. The goal of the trial will be to find the maximum dose of indoximod that does not induce RLT in more than 1/6 of patients treated with temozolomide.
- Overall Dose of Temozolomide Delivered Versus Historical Control [ Time Frame: 1 year ]To test the hypothesis that the addition of indoximod will not reduce the overall dose of temozolomide delivered or delay the timing of administration, compared to historical controls using T-test.
- Serum concentrations (Cmax/Steady State) of indoximod HLC [ Time Frame: 1 year ]
Phase 1b component:
To determine the pharmacokinetic profile of indoximod in the setting of this treatment regimen. A thorough pharmacokinetic (PK) profile will be performed for each patient entered into the study through analysis of blood samples collected at protocol-defined time points.
- Overall response rate [ Time Frame: 18 months ]Assessed for Arms 2a, 2b and 2c
- Number of Participants with Adverse Events as a Measure of Safety and Tolerability [ Time Frame: 18 Months ]Assessed for Arms 2a, 2b and 2c
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 16 Years and older (Child, Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Histologically proven intracranial glioblastoma multiforme (WHO grade IV glioma) or gliosarcoma. In addition, the Phase 1b cohort will include patients with progressive WHO grade III glioma.
- Patients will be eligible if the original histology was lower grade glioma and a subsequent diagnosis of glioblastoma or gliosarcoma is made.
- Unequivocal radiographic evidence for tumor progression by MRI. It is understood that some patients may be resected prior to enrolling onto protocol
- Patients must have completed a course of radiation therapy and at least 2 adjuvant cycles of temozolomide for the phase 2 component.
- Patients enrolling onto Cohort 2b who have been taken off bevacizumab must have had at least a 28 day washout from any previous administration of bevacizumab. It is preferred that patients who fail bevacizumab prior to trial entry remain on bevacizumab in the trial.
- Prior temozolomide is not required for the phase 1 component; prior radiation is required for the phase 1 arm.
- Patients must be on a steroid dose less than or equal to 2 mg of dexamethasone daily (or equivalent), and this dose must not have increased for at least 14 days prior to obtaining the enrollment.
- ECOG performance status ≤1 or Karnofsky ≥70%.
- Age between 16
- Must be 28 days from the administration of any investigational agent or prior cytotoxic therapy with the following exceptions:
- Must be 14 days from administration of non-cytotoxic agents (e.g., bevacizumab (except COHORT 2b), interferon, tamoxifen, thalidomide, cis-retinoic acid, tyrosine kinase inhibitor, etc.).
Exclusion Criteria:
- Prior invasive malignancy that is not low-grade glioma, high-grade glioma, glioblastoma, or gliosarcoma (except non-melanomatous skin cancer or carcinoma in situ of the cervix) unless the patient has been disease free and off therapy for that disease for a minimum of 3 years.
- Patients on the phase 2 portion of the study may not have more than 2 prior regimens for recurrent disease for glioblastoma/gliosarcoma. Patients on the phase 1 portion of the study may not have had more than 3 prior regimens.
- Systemic corticosteroid therapy > 2 mg of dexamethasone daily (or equivalent) at study enrollment.
- Active or history of autoimmune disease
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02052648
Show 17 study locations
| Responsible Party: | NewLink Genetics Corporation |
| ClinicalTrials.gov Identifier: | NCT02052648 |
| Other Study ID Numbers: |
NLG2102 |
| First Posted: | February 3, 2014 Key Record Dates |
| Last Update Posted: | May 28, 2020 |
| Last Verified: | May 2020 |
|
glioblastoma multiforme glioma gliosarcoma malignant brain tumor |
|
Glioblastoma Brain Neoplasms Gliosarcoma Neoplasms Astrocytoma Glioma Neoplasms, Neuroepithelial Neuroectodermal Tumors Neoplasms, Germ Cell and Embryonal Neoplasms by Histologic Type Neoplasms, Glandular and Epithelial Neoplasms, Nerve Tissue Central Nervous System Neoplasms Nervous System Neoplasms Neoplasms by Site |
Brain Diseases Central Nervous System Diseases Nervous System Diseases Bevacizumab Temozolomide Tryptophan Antineoplastic Agents, Immunological Antineoplastic Agents Angiogenesis Inhibitors Angiogenesis Modulating Agents Growth Substances Physiological Effects of Drugs Growth Inhibitors Antineoplastic Agents, Alkylating Alkylating Agents |